ALSO NOTED: Ipsen licenses Acapodene; Committee recommends Fragmin; and much more...

> France's Ipsen has agreed to pay $30 million to license GTx's Acapodene for all indications except breast cancer in Europe. Acapodene is in Phase III for cancer prevention. Report

> An FDA advisory committee has recommended that the agency expand the approval of Pfizer's Fragmin to include the prevention of blood clots in cancer patients. Report

> The newly renamed Caden Biosciences raised $5.85 million in venture capital and is moving to Wisconsin. Report

> Metastatix, an Atlanta-based biopharmaceutical company developing small-molecule drugs to treat cancer and HIV, announced today it has raised a $3.6 million Series A financing round. Release

> The Wall Street Journal provides a blow-by-blow account of Bristol-Myers Squibb's disastrous campaign to hold onto Plavix. CEO Peter Dolan comes in for a large portion of the blame. Article

> Sanofi-Aventis has pulled its marketing application for the heart arrhythmia therapy Multaq following last month's FDA rejection and fresh competition from generic Plavix. Report

> Chutes & Ladders: Celsion CEO Lawrence Olanoff has resigned to return to Forest Labs as COO. CFO Anthony Deasey will be interim CEO. Report

> Zestra Laboratories of Charleston, SC has raised $6 million in a private placement. Release

> A federal appeals court has ruled that Mylan Laboratories did not infringe on J&J's patent of a urinary incontinence therapy. Report

And Finally… Better therapies and earlier interventions are helping drive down the rate of deaths from cancer in the United States, with the biggest declines for men. Article